Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors.
Falanga A, Marchetti M, Massi D, Merelli B, Verzeroli C, Russo L, Rulli E, Tondini C, Legramandi L, Nassini R, Scatena C, De Logu F, Cattaneo L, Mandalà M. Falanga A, et al. Among authors: legramandi l. J Am Acad Dermatol. 2016 Jun;74(6):1254-1256.e4. doi: 10.1016/j.jaad.2015.11.006. J Am Acad Dermatol. 2016. PMID: 27185428 No abstract available.
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
Cazzaniga ME, Cortesi L, Ferzi A, Scaltriti L, Cicchiello F, Ciccarese M, Della Torre S, Villa F, Giordano M, Verusio C, Nicolini M, Gambaro AR, Zanlorenzi L, Biraghi E, Legramandi L, Rulli E; VICTOR Study Group. Cazzaniga ME, et al. Among authors: legramandi l. Breast Cancer Res Treat. 2016 Dec;160(3):501-509. doi: 10.1007/s10549-016-4009-3. Epub 2016 Oct 17. Breast Cancer Res Treat. 2016. PMID: 27752847 Free PMC article. Clinical Trial.
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
Cazzaniga ME, Cortesi L, Ferzi A, Scaltriti L, Cicchiello F, Ciccarese M, Torre SD, Villa F, Giordano M, Verusio C, Nicolini M, Gambaro AR, Zanlorenzi L, Biraghi E, Casini E, Legramandi L, Rulli E. Cazzaniga ME, et al. Among authors: legramandi l. Int J Breast Cancer. 2017;2017:1683060. doi: 10.1155/2017/1683060. Epub 2017 Dec 3. Int J Breast Cancer. 2017. PMID: 29333297 Free PMC article. Review.
Influence of Sociodemographic Factors on Disease Characteristics and Vision-related Quality of Life in Primary Open-angle Glaucoma Patients: The Italian Primary Open Angle Glaucoma Study (IPOAGS).
Riva I, Legramandi L, Katsanos A, Oddone F, Rulli E, Roberti G, Quaranta L; Italian Study Group on QoL in Glaucoma. Riva I, et al. Among authors: legramandi l. J Glaucoma. 2018 Sep;27(9):776-784. doi: 10.1097/IJG.0000000000000989. J Glaucoma. 2018. PMID: 29781833
Oral prolonged-release Oxycodone-Naloxone: analgesic response, safety profile, and factors influencing the response in advanced cancer patients.
Corli O, Iorno V, Legramandi L, Rulli E, Roberto A, Azzarello G, Schiavon S, Cavanna L, De Santis S, Cartoni C, Di Marco P, Dauri M, Mistretta R, Bortolussi R, Clerico M, Pacchioni M, Crispino C, Marabese M, Corsi N; GREAT Collaborators. Corli O, et al. Among authors: legramandi l. Pain Pract. 2019 Mar 27. doi: 10.1111/papr.12784. Online ahead of print. Pain Pract. 2019. PMID: 30917409
15 results